Halozyme Therapeutics (HALO) Goodwill & Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Goodwill & Intangibles data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Goodwill & Intangibles rose 91.57% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 91.57% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 90.78% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• Over the last five years, Goodwill & Intangibles for HALO reached as high as $1.6 billion in Q4 2025 and fell as low as $765.4 million in Q3 2025.
• Historically, Goodwill & Intangibles has averaged $986.0 million across 5 years, with a median of $898.6 million in 2023.
• Across the five-year window, Goodwill & Intangibles dropped 21.08% in 2023 and surged 91.57% in 2026, its largest moves.
• Year by year, Goodwill & Intangibles stood at $955.7 million in 2022, then fell by 6.91% to $889.7 million in 2023, then dropped by 7.99% to $818.7 million in 2024, then jumped by 90.78% to $1.6 billion in 2025, then retreated by 1.76% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Goodwill & Intangibles figures were $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $765.4 million in Q3 2025.